Floatz logo

Oxodotreotide

Pheochromocytoma/Paragangliomas

National Cancer Institute (NCI)protein_peptidePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Pheochromocytoma/Paragangliomas cohort.

Asset / SponsorPhaseRating
Oxodotreotide
National Cancer Institute (NCI)
Phase 1/2CCC
FAPI74
National Cancer Institute (NCI)
Phase 2CCC
FLUDEOXYGLUCOSE
National Cancer Institute (NCI)
Phase 2CCC
Olaparib
Fundación de investigación HM
Phase 1/2CCC
[212pb]vmt-alpha-net
National Cancer Institute (NCI)
Phase 1CC

Same molecule, other indications

Oxodotreotide is also rated in:

pancreatic neuroendocrine tumorDormant
BBB
Indicative ·
75 / 100
View asset →
digestive system neuroendocrine neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
digestive system neuroendocrine tumor, grade 1/2Dormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →